Year: 2023

HIGHfield_logo_horizontal_FINAL_English

HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers

The company’s groundbreaking drug encapsulated immunoliposomes may represent a significant improvement over existing antibody drug conjugates HANGZHOU, China--(BUSINESS WIRE)--HighField Biopharmaceuticals,...